OraSure Technologies (NASDAQ:OSUR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. “
Other equities research analysts have also issued reports about the stock. Jefferies Group reaffirmed a “buy” rating and set a $23.00 price target on shares of OraSure Technologies in a report on Friday, October 20th. Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 price target on shares of OraSure Technologies in a report on Tuesday, September 19th. BidaskClub raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Finally, ValuEngine lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $19.65.
Shares of OraSure Technologies (NASDAQ OSUR) traded down $0.03 during mid-day trading on Tuesday, hitting $19.39. 268,200 shares of the stock were exchanged, compared to its average volume of 655,814. OraSure Technologies has a fifty-two week low of $8.39 and a fifty-two week high of $23.01. The stock has a market cap of $1,180.00, a P/E ratio of 37.29, a PEG ratio of 4.58 and a beta of 1.27.
OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.09. The business had revenue of $42.30 million for the quarter, compared to the consensus estimate of $40.87 million. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The business’s revenue for the quarter was up 31.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.11 EPS. analysts forecast that OraSure Technologies will post 0.43 earnings per share for the current year.
In other news, Director Mara G. Aspinall purchased 5,000 shares of the stock in a transaction that occurred on Tuesday, November 7th. The stock was acquired at an average cost of $14.23 per share, with a total value of $71,150.00. Following the acquisition, the director now owns 5,000 shares in the company, valued at $71,150. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 6.40% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Profund Advisors LLC grew its holdings in OraSure Technologies by 2.8% during the 2nd quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock worth $188,000 after acquiring an additional 293 shares in the last quarter. Victory Capital Management Inc. grew its holdings in OraSure Technologies by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 1,360 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in OraSure Technologies by 3.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,672 shares of the medical instruments supplier’s stock worth $772,000 after acquiring an additional 1,573 shares in the last quarter. Rhumbline Advisers grew its holdings in OraSure Technologies by 2.3% during the 2nd quarter. Rhumbline Advisers now owns 106,594 shares of the medical instruments supplier’s stock worth $1,840,000 after acquiring an additional 2,428 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in OraSure Technologies by 0.7% during the 3rd quarter. Principal Financial Group Inc. now owns 482,574 shares of the medical instruments supplier’s stock worth $10,858,000 after acquiring an additional 3,531 shares in the last quarter. 94.43% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/11/zacks-investment-research-upgrades-orasure-technologies-osur-to-hold-3.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.